TROPONIN T, TROPONIN I NEED FURTHER STUDY TO CLARIFY THE MOST EFFECTIVE USE OF CARDIAC MARKER TESTS, PHYSICIAN SAYS IN NEJM EDITORIAL
This article was originally published in The Gray Sheet
Additional studies are needed to establish the optimal usefulness of tests for troponin T and troponin I serum cardiac markers in the assessment of mortality risk from acute coronary syndromes, according to Frans Van De Werf, MD, University Hospital Gasthuisberg, Leuven, Belgium, writing in the Oct. 31 issue of the New England Journal of Medicine.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.